Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells

KM Dhodapkar, JL Kaufman, M Ehlers… - Proceedings of the …, 2005 - National Acad Sciences
KM Dhodapkar, JL Kaufman, M Ehlers, DK Banerjee, E Bonvini, S Koenig, RM Steinman…
Proceedings of the National Academy of Sciences, 2005National Acad Sciences
The final differentiation or maturation of dendritic cells (DCs) in response to environmental
stimuli influences their ability to both initiate immunity and determine the quality of the
response to antigens. Circulating immune complexes and cell-bound immunoglobulins
present in normal human sera represent a potential stimulus for inadvertent DC activation in
the steady state and during autoimmunity. Here, we show that selective blockade of the
inhibitory Fcγ receptor (FcγR) FcγRIIb with recently developed monoclonal antibodies leads …
The final differentiation or maturation of dendritic cells (DCs) in response to environmental stimuli influences their ability to both initiate immunity and determine the quality of the response to antigens. Circulating immune complexes and cell-bound immunoglobulins present in normal human sera represent a potential stimulus for inadvertent DC activation in the steady state and during autoimmunity. Here, we show that selective blockade of the inhibitory Fcγ receptor (FcγR) FcγRIIb with recently developed monoclonal antibodies leads to maturation of human monocyte-derived DCs, which depends on the presence of IgG in normal human plasma. Plasma, in the presence of an FcγRIIb blockade, caused the DCs to up-regulate the expression of costimulatory molecules and to produce the inflammatory mediator IL-12p70. FcγRIIb blockade of DCs loaded with tumor cells led to increased tumor-specific T cell immunity without the need for exogenous stimuli other than human plasma. Therefore, the activation status of DCs in the presence of normal human serum depends on the balance between activating and inhibitory FcγRs and can be enhanced by new antibodies that react selectively with FcγRIIb. These data suggest an approach for modifying this balance to enhance immunity to immune complexes and antibody-coated tumor cells and to silence DC activation by immune complexes in autoimmune states.
National Acad Sciences